PMID- 11098350
OWN - NLM
STAT- MEDLINE
DCOM- 20010308
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 34
IP  - 11
DP  - 2000 Nov
TI  - Spironolactone in the treatment of congestive heart failure.
PG  - 1336-40
AB  - OBJECTIVE: To evaluate evidence supporting the use of spironolactone in managing 
      congestive heart failure. DATA SOURCES: Literature accessed through MEDLINE 
      (January 1966-December 1999) and cross-referencing of selected articles. Search 
      terms included spironolactone and heart failure. DATA SYNTHESIS: Heart failure is 
      a leading cause of morbidity and mortality. Through aldosterone antagonism, 
      spironolactone may be an effective pharmacotherapeutic addition to patients not 
      responding to standard drug therapy for heart failure. RESULTS: Clinical trials 
      have demonstrated that, in patients with heart failure, spironolactone improves 
      laboratory indices, quality of life, and morbidity. Recently, spironolactone has 
      been demonstrated to improve the survival of patients with New York Heart 
      Association (NYHA) III or IV heart failure. CONCLUSIONS: Spironolactone use 
      should be considered in patients with NYHA Class III or IV heart failure.
FAU - Lloyd, S J
AU  - Lloyd SJ
AD  - College of Pharmacy, University of Toledo, OH 43606, USA.
FAU - Mauro, V F
AU  - Mauro VF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 27O7W4T232 (Spironolactone)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Hyperkalemia/chemically induced
MH  - Mineralocorticoid Receptor Antagonists/adverse effects/*therapeutic use
MH  - Quality of Life
MH  - Spironolactone/adverse effects/*therapeutic use
RF  - 20
EDAT- 2000/12/01 11:00
MHDA- 2001/03/10 10:01
CRDT- 2000/12/01 11:00
PHST- 2000/12/01 11:00 [pubmed]
PHST- 2001/03/10 10:01 [medline]
PHST- 2000/12/01 11:00 [entrez]
AID - 10.1345/aph.10104 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2000 Nov;34(11):1336-40. doi: 10.1345/aph.10104.